Cleavage and polyadenylation specificity factor 1 (CPSF1) regulates alternative splicing of interleukin 7 receptor (IL7R) exon 6

RNA

Volumn 19, Issue 1, 2013, Pages 103-115

  Evsyukova, Irina ^a   Bradrick, Shelton S ^a   Gregory, Simon G ^a   Garcia Blanco, Mariano A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alternative splicing; CPSF1; IL7R; Multiple sclerosis; Polyadenylation

Indexed keywords

CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR 1; INTERLEUKIN 7 RECEPTOR; MESSENGER RNA; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ALLELE; ALTERNATIVE RNA SPLICING; ARTICLE; DOWN REGULATION; EXON; GENE MUTATION; INTRON; MASS SPECTROMETRY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ALTERNATIVE SPLICING; ANIMALS; CELL LINE; CHROMATOGRAPHY, AFFINITY; CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; EXONS; GENE SILENCING; HUMANS; INTRONS; MASS SPECTROMETRY; MULTIPLE SCLEROSIS; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN ISOFORMS; RATS; RECEPTORS, INTERLEUKIN-7; RNA SPLICE SITES; RNA, MESSENGER; SPLICEOSOMES; TRANS-ACTIVATORS;

EID: 84871458999     PISSN: 13558382     EISSN: 14699001     Source Type: Journal    
DOI: 10.1261/rna.035410.112     Document Type: Article

References (60)

1. Akashi K, Kondo M, von Freeden-Jeffry U, Murray R, Weissman IL. 1997. Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor-deficient mice. Cell 89: 1033-1041.
2. Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, Lee JC, Goyette P, Imelinski M, Latiano A, et al. 2011. Meta-analysis identifies 29 additinoal ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 43: 246-252.
3. Berg MG, Singh LN, Younis I, Liu Q, Pinto AM, Kaida D, Zhang Z, Cho S, Sherrill-Mix S, Wan L, et al. 2012. U1 snRNP determines mRNA length and regulates isoform expression. Cell 150: 53-64.
4. Campigli Di Giammartino D, Nishida K, Manley JL. 2011. Mechanisms and consequences of alternative polyadenylation. Mol Cell 43: 853-866.
5. Carstens RP, McKeehan WL, Garcia-Blanco MA. 1998. An intronic sequence element mediates both activation and repression of rat fibroblast growth factor receptor 2 pre-mRNA splicing. Mol Cell Biol 18: 2205-2217.
6. Chuvpilo S, Zimmer M, Kerstan A, Glöckner J, Avots A, Escher C, Fischer C, Inashkina I, Jankevics E, Berberich-Siebelt F, et al. 1999. Alternative polyadenylation events contribute to the induction of NF-ATc in effector T cells. Immunity 10: 261-269.
7. Cooke C, Hans H, Alwine JC. 1999. Utilization of splicing elements and polyadenylation signal elements in the coupling of polyadenylation and last-intron removal. Mol Cell Biol 19: 4971-4979.
8. Cooper TA, Wan L, Dreyfuss G. 2009. RNA and disease. Cell 136: 777-793.
9. Crawley AM, Faucher S, Angel JB. 2010. Soluble IL-7Ra (sCD127) inhibits IL-7 activity and is increased in HIV infection. J Immunol 184: 4679-4687.
10. Danckwardt S, Hentze MW, Kulozik AE. 2008. 3′ end mRNA processing: molecular mechanisms and implications for health and disease. EMBO J 27: 482-498.
11. Dignam JD, Lebovitz RM, Roeder RG. 1983. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11: 1475-1489.
12. Evsyukova I, Somarelli JA, Gregory SG, Garcia-Blanco MA. 2010. Alternative splicing in multiple sclerosis and other autoimmune diseases. RNA Biol 7: 462-473.
13. Franchimont D, Galon J, Vacchio MS, Fan S, Visconti R, Frucht DM, Geenen V, Chrousos GP, Ashwell JD, O'Shea JJ. 2002. Positive effects of glucocorticoids on T cell function by up-regulation of IL-7 receptor alpha. J Immunol 168: 2212-2218.
14. Garcia-Blanco MA, Baraniak AP, Lasda EL. 2004. Alternative splicing in disease and therapy. Nat Biotechnol 22: 535-546.
15. Goldstrohm AC, Greenleaf AL, Garcia-Blanco MA. 2001. Co-transcriptional splicing of pre-messenger RNAs: considerations for the mechanism of alternative splicing. Gene 277: 31-47.
16. Goodwin RG, Friend D, Ziegler SF, Jerzy R, Falk BA, Gimpel S, Cosman D, Dower SK, March CJ, Namen AE, et al. 1990. Cloning of the human and murine interleukin-7 receptors: demonstration of a soluble form and homology to a new receptor superfamily. Cell 60: 941-951.
17. Gregory SG, Schmidt S, Seth P, Oksenberg JR, Hart J, Prokop A, Caillier SJ, Ban M, Goris A, Barcellos LF, et al. 2007. Interleukin 7 receptor a (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 39: 1083-1091.
18. Hartmuth K, Vornlocher HP, Lührmann R. 2004. Tobramycin affinity tag purification of spliceosomes. Methods Mol Biol 257: 47-64.
19. Heron M, Grutters JC, van Moorsel CHM, Ruven HJT, Huizinga TWJ, van der Helm-van Mil AHM, Claessen AME, van den Bosch JMM. 2009. Variation in IL7R predisposes to sarcoid inflammation. Genes Immun 10: 647-653.
20. The International Multiple Sclerosis Genetics Consortium. 2007. Risk alleles for multiple sclerosis identified by a genome-wide study. N Engl J Med 357: 851-862.
21. Jiang Q, Li WQ,Hofmeister RR, YoungHA, HodgeDR, Keller JR,Khaled AR, Durum SK. 2004. Distinct regions of the interleukin-7 receptor regulate different Bcl2 family members. Mol Cell Biol 24: 6501-6513.
22. Kaida D, Berg MG, Younis I, Kasim M, Singh LN, Wan L, Dreyfuss G. 2010. U1 snRNP protects pre-mRNAs from premature cleavage and polyadenylation. Nature 468: 664-669.
23. Kalman L, Lindegren ML, Kobrynski L, Vogt R, Hannon H, Howard JT, Buckley R. 2004. Mutations in genes required for T-cell development: IL7R, CD45, IL2RG, JAK3, RAG1, RAG2, ARTEMIS, and ADA and severe combined immunodeficiency: HuGE review. Genet Med 6: 16-26.
24. Keller W, Bienroth S, Lang KM, Christofori G. 1991. Cleavage and polyadenylation factor CPF specifically interacts with the premRNA 3′ processing signal AAUAAA. EMBO J 10: 4241-4249.
25. Koesters SA, Alimonti JB, Wachihi C, Matu L, Anzala O, Kimani J, Embree JE, Plummer FA, Fowke KR. 2006. IL-7R a expression on CD4+ T lymphocytes decreases with HIV disease progression and inversely correlates with immune activation. Eur J Immunol 36: 336-344.
26. Korte A, Köchling J, Badiali L, Eckert C, Andreae J, Geilen W, Kebelmann-Betzing C, Taube T, Wu S, Henze G, et al. 2000. Expression analysis and characterization of alternatively spliced transcripts of human IL-7Ra chain encoding two truncated receptor proteins in relapsed childhood ALL. Cytokine 12: 1597-1608.
27. Kyburz A, Friedlein A, Langen H, Keller W. 2006. Direct interactions between subunits of CPSF and the U2 snRNP contribute to the coupling of pre-mRNA 3′ end processing and splicing. Mol Cell 23: 195-205.
28. Li Y, Chen Z-Y, Wang W, Baker CC, Krug RM. 2001. The 3′-end- processing factor CPSF is required for the splicing of single-intron pre-mRNAs in vivo. RNA 7: 920-931.
29. Lou H, Neugebauer KM, Gagel RF, Berget SM. 1998. Regulation of alternative polyadenylation by U1 snRNPs and SRp20. Mol Cell Biol 18: 4977-4985.
30. Lundmark F, Duvefelt K, Iacobaeus E, Kockum I, Wallström E, Khademi M, Oturai A, Ryder LP, Saarela J, Harbo HF, et al. 2007. Variation in interleukin 7 receptor a chain (IL7R) influences risk of multiple sclerosis. Nat Genet 39: 1108-1113.
31. Lutz CS. 2008. Alternative polyadenylation: a twist on mRNA 3′ end formation. ACS Chem Biol 3: 609-617.
32. Lutz CS, Moreira A. 2011. Alternative mRNA polyadenylation in eukaryotes: an effective regulator of gene expression. Wiley Interdiscip Rev RNA 2: 23-31.
33. Lutz CS, Murthy KGK, Schek N, O'Connor JP, Manley JL, Alwine JC. 1996. Interaction between the U1 snRNP-A and the 160-kD subunit of cleavage-polyadenylation specificity factor increases polyadenylation efficiency in vitro. Genes Dev 10: 325-337.
34. Lynch KW. 2004. Consequences of regulated pre-mRNA splicing in the immune system. Nat Rev Immunol 4: 931-940.
35. Maki K, Sunaga S, Ikuta K. 1996. The V-J recombination of T cell receptor-g genes is blocked in interleukin-7 receptor-deficient mice. J Exp Med 184: 2423-2427.
36. Mazzucchelli R, Durum SK. 2007. Interleukin-7 receptor expression: intelligent design. Nat Rev Immunol 7: 144-154.
37. Mells GF, Floyd JA, Morley KI, Cordell HJ, Franklin CS, Shin SY, Heneghan MA, Neuberger JM, Donaldson PT, Day DB, et al. 2011. Genome-wide association study identified 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet 43: 329-332.
38. Millevoi S, Geraghty F, Idowu B, Tam JL, Antoniou M, Vagner S. 2002. A novel function for the U2AF 65 splicing factor in promoting pre-mRNA 3′-end processing. EMBO Rep 3: 869-874.
39. Millevoi S, Loulergue C, Dettwiler S, Karaa SZ, Keller W, Antoniou M, Vagner S. 2006. An interaction between U2AF 65 and CF I(m) links the splicing and 3′ processing machineries. EMBO J 25: 4854-4864.
40. Murthy KG, Manley JL. 1995. The 160-kD subunit of human cleavage-polyadenylation specificity factor coordinates pre-mRNA 3′-end formation. Genes Dev 9: 2672-2683.
41. Niwa M, Berget SM. 1991. Mutation of the AAUAAA polyadenylation signal depresses in vitro splicing of proximal but not distal introns. Genes Dev 5: 2086-2095.
42. Park JH, Yu Q, Erman B, Appelbaum JS, Montoya-Durango D, Grimes HL, Singer A. 2004. Suppression of IL7Ra transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival. Immunity 21: 289-302.
43. Peschon JJ, Morrissey PJ, Grabstein KH, Ramsdell FJ, Maraskovsky E, Gliniak BC, Park LS, Ziegler SF, Williams DE, Ware CB, et al. 1994. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med 180: 1955-1960.
44. Pleiman CM, Gimpel SD, Park LS, Harada H, Taniguchi T, Ziegler SF. 1991. Organization of the murine and human interleukin-7 receptor genes: two mRNAs generated by differential splicing and presence of a type I-interferon-inducible promoter. Mol Cell Biol 11: 3052-3059.
45. Proudfoot NJ. 2011. Ending the message: poly(A) signals then and now. Genes Dev 25: 1770-1782.
46. + severe combined immunodeficiency. Nat Genet 20: 394-397.
47. Rose T, Lambotte O, Pallier C, Delfraissy J-F, Colle J-H. 2009. Identification and biochemical characterization of human plasma soluble IL-7R: lower concentrations in HIV-1-infected patients. J Immunol 182: 7389-7397.
48. Sandberg R, Neilson JR, Sarma A, Sharp PA, Burge CB. 2008. Proliferating cells express mRNAs with shortened 3′ untranslated regions and fewer microRNA target sites. Science 320: 1643-1647.
49. Singh P, Alley TL, Wright SM, Kamdar S, Schott W, Wilpan RY, Mills KD, Graber JH. 2009. Global changes in processing of mRNA 3′ untranslated regions characterize clinically distinct cancer subtypes. Cancer Res 69: 9422-9430.
50. Takagaki Y, Manley JL. 1998. Levels of polyadenylation factor CstF-64 control IgM heavy chain mRNA accumulation and other events associated with B cell differentiation. Mol Cell 2: 761-771.
51. Takagaki Y, Seipelt RL, Peterson ML, Manley JL. 1996. The polyadenylation factor CstF-64 regulates alternative processing of IgM heavy chain pre-mRNA during B cell differentiation. Cell 87: 941-952.
52. Tian B, Pan Z, Lee JY. 2007. Widespread mRNA polyadenylation events in introns indicate dynamic interplay between polyadenylation and splicing. Genome Res 17: 156-165.
53. Trapp BD, Nave K-A. 2008. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 31: 247-269.
54. Vagner S, Vagner C, Mattaj IW. 2000. The carboxyl terminus of vertebrate poly(A) polymerase interacts with U2AF 65 to couple 3′-end processing and splicing. Genes Dev 14: 403-413.
55. Vorlová S, Rocco G, LeFave CV, Jodelka FM, Hess K, Hastings ML, Henke E, Cartegni L. 2011. Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic polyA activation. Mol Cell 43: 927-939.
56. Wang G-S, Cooper TA. 2007. Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet 8: 749-761.
57. Ward AM, Bidet K, Yinglin A, Ler SG, Hogue K, Blackstock W, Gunaratne J, Garcia-Blanco MA. 2011. Quantitative mass spectrometry of DENV-2 RNA-interacting proteins reveals that the DEAD-box RNA helicase DDX6 binds the DB1 and DB2 3′ UTR structures. RNA Biol 8: 1173-1186.
58. Xue H-H, Kovanen PE, Rise-Masisom CA, Berg M, Radovich MF, Brady JN, Leonard WJ. 2002. IL-2 negatively regulates IL-7 receptor a chain expression in activated T lymphocytes. Proc Natl Acad Sci 99: 13759-13764.
59. Yamazaki M, Yajima T, Tanabe M, Fukui K, Okada E, Okamoto R, Oshima S, Nakamura T, Kanai T, Uehira M, et al. 2003. Mucosal T cells expressing high levels of IL-7 receptor are potential targets for treatment of chronic colitis. J Immunol 171: 1556-1563.
60. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Easton J, Chen X, Wang I, Rusch M, et al. 2012. The genetic basis of early T-cell precursor acute lymphoblastic leukemia. Nature 481: 157-163.